Pacemaker Syndrome with AAI Rate Variable Pacing: Importance of Atrioventricular Conduction Properties, Medication, and Pacemaker Programmability

• Published in: Pacing and clinical electrophysiology 1988-08, Vol.11 (8), p.1226-1233
• Main Authors: DULK, KAREL, LINDEMANS, FRED W., BRUGADA, PEDRO, SMEETS, JOEP L.R.M., WELLENS, HEIN J.J.
• Format: Article
• Language: English
• Subjects: AAI pacing; AAI rate variable pacing; Aged; Atrioventricular Node - physiopathology; Bradycardia - therapy; Disopyramide - therapeutic use; Dizziness - etiology; dual AV nodal pathways; Equipment Design; Exercise; Heart Conduction System - physiopathology; Humans; Hypotension - etiology; Male; Pacemaker, Artificial - adverse effects; refractory period during AAI pacing; Syncope - etiology; Syndrome
• ISSN: 0147-8389; 1540-8159
• DOI: 10.1111/j.1540-8159.1988.tb03976.x

A patient who received an AAI Activitrax rate variable pacemaker for treatment of symptomatic sinus bradycardia is described, disopyramide prolonged the anterograde effective refractory period of the fast conducting atrioventricular (AV) nodal pathway to such an extent, that conduction switched to the slow AV nodal pathway at low atrial pacing rates. This gave rise to symptoms of the pacemaker syndrome during moderate exercise because the paced atrial event was conducted with a long, spike to Q interval with occurrence of the paced atrial event just after the preceding QRS complex. A change of medication solved this problem. Programming a bipolar electrode configuration avoided sensing of far‐field QRS signals with the associated problems of resetting the basic pacing interval as well as the upper rate interval. AAI rate variable pacing requires careful evaluation of AV conduction properties, AV conduction intervals as well as the influence of medication to be given. The use of multiprogrammable pacemakers with marker channel capability will significantly facilitate the understanding and resolution of anomalous behavior.